[Blood-brain barrier pathophysiology and ischaemic brain oedema].
Cerebral oedema is a potentially lethal complication of brain infarction. Ischemia, by altering membrane ionic pump function, induces cell swelling and cytotoxic oedema. It also initiates early oxidative and inflammatory cascades leading to blood-brain barrier disruption, vasogenic oedema and haemorrhagic transformation. The mechanisms of blood-brain barrier disruption involve endothelial cell activation and endothelial basal membrane degradation by matrix metalloproteinases. Reperfusion by tissue plasminogen activators is the only treatment improving stroke prognosis. This treatment also increases vasogenic oedema and the risk of symptomatic haemorrhagic transformation, reducing the benefit of reperfusion. Experimental studies suggest that the inhibition of blood-brain barrier proteolysis reduces vasogenic oedema and the risk of haemorrhage. This recent progress in the understanding of blood-brain barrier disruption during ischaemia brings forward new therapeutic strategies using agents capable of interfering with the ischaemic cascade in order to increase the therapeutic window between the onset of ischaemia and thrombolytic reperfusion.
Gasche
Y
Y
Division des soins intensifs de chirurgie, département de pharmacologie, d'anesthésiologie et des soins intensifs de chirurgie, Genève, Suisse. yvan.gasche@medecine.unige.ch <yvan.gasche@medecine.unige.ch>
Copin
J-C
JC
D001812:Blood-Brain Barrier / Q000502:physiology*; D001929:Brain Edema / Q000209:etiology / Q000503:physiopathology; D002545:Brain Ischemia / Q000209:etiology / Q000503:physiopathology*; D002544:Cerebral Infarction / Q000150:complications; D006801:Humans; D015424:Reperfusion; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
D010959:Tissue Plasminogen Activator